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Abstract 
Her3/erbB3 has been identified as a third member of the epidermal growth factor receptor (EGFR) family [(1989) Proc. Natl. Acad. Sci. USA 86, 
9193-9197; (1990) Proc. Natl. Acad. Sci. USA 87,4905-1909]. The natural ligand for Her3 has not been identified. Although recently NDF has been 
proposed as a specific ligand for Her4 [(1993) Nature 366, 473475; (1993) J. Biol. Chem. 268, 18407-184101, we report here that Her3 was 
phosphorylated on tyrosine not only in three breast carcinoma cell lines, MDAMB453, MDAMB468 and SKBR3, but also in Her3-transfected CHO 
cells in response to NDF stimulation. In further studies, cells were reacted with ‘251-labeled NDF and then chemically crosslinked. Immunoprecip- 
itation with anti-Her3 revealed a dense high Mw band, greater than 400 kDa. The results suggest that NDF may be a ligand of Her3 and induces 
receptor hetero-oligomerization. 
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1. Introduction 
Members of the erbB growth factor receptor family 
are frequently over-expressed in a variety of epithelial 
carcinomas [5-71. The four erbB family receptors identi- 
fied thus far (EGFR, erbB2/Her2, erbBUHer3 and 
erbBWHer4) possess 60-80% homology in their kinase 
domains [8,9]. EGF, TGFa, amphiregulin, heparin bind- 
ing EGF and betacellulin have been identified as the 
EGFR ligands [lo-l 51. A 25 kDa (~25) peptide from 
conditioned media of MDP-activated macrophages 
(MDP-CM) [16], NAF (a v protein-specific activating 
factor) [17], a 75 kDa (P75) peptide from SKBR3 condi- 
tioned media [ 181, NEL-GF from bovine kidney [19], 
NDF/heregulin [20], ARIA (a factor that stimulates the 
synthesis of acetylcholine receptors [21] and GGF (glial 
growth factor) [22], have been proposed as ligands of 
~185 erbB2’Her2. Evidence for the interaction of NDF with 
Her2 was derived from studies with cultured human car- 
cinomas in which the Her2 gene was frequently ampli- 
fied, but which also expressed other members of the 
EGFR family. Recent experiments in transfected rodent 
cells expressing only the Her2 gene have failed to confirm 
the existence of direct interaction between NDF and 
Her2 (data not shown). We and others [23] have theo- 
rized that the activation of Her2 receptor tyrosine kinase 
in response to NDF may require the active participation 
of another receptor, which may initially bind the ligand 
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and secondarily phosphorylate the Her2 through recep- 
tor cross-talk [24-261. We have focused on Her3/erbB3 
as the receptor which potentially [runs-phosphorylates 
Her2 since both receptors were found to be expressed in 
the breast cancer cell lines used for these studies (SKBR3 
and MDAMB453) [27]. Two groups isolated Her3/erbB3 
independently as a third member of the EGFR family 
[ 1,2], and a natural ligand for Her3 has not yet been 
identified. Some doubts initially existed that Her3 pos- 
essed tyrosine kinase, due to the presence of unusual 
amino acids in its catalytic domain. However, in vitro 
kinase activity has now been demonstrated in Her3 
transfected into NIH3T3 cells, and a chimeric EGFRI 
erbB3 protein was shown to be activated by EGF [27]. 
We show in this paper that NDF induces tyrosine phos- 
phorylation of Her3 in both breast carcinoma cells and 
HeD-transfected CHO cells. 
2. Materials and methods 
2.1. Cells 
Her3/CHO cells were prepared by co-transfection of DHFR-defi- 
cient CHO cells with two vectors: pJT2 carrying the genes for erbB3 
gene and dihydrofolate reductase (dhfr) in pDRa2. ErbB3-transfected 
CHO cells were grown in selective medium which lacked nucleosides 
(DMEM containing 5% dialyzed fetal bovine serum, 2 mM glutamine 
and 0.1 mM non-essential amino acids). 
2.2. Materials 
Human recombinant EGF and NDF isofonns were produced in 
E. coli, and purified to greater than 98% homogeneity by subjecting 
clarified E. coli lysates to anion exchange, cation exchange, hydropho- 
bic interaction and hydroxyapatite column chromatography. Extra 
methionine residues were added at the N-terminus of NDF as initiation 
sites for protein translation. Anti-Her3 polyclonal antibodies, 61.3 and 
49.3 (affinity purified), were used for immunoprecipitation and Western 
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blotting [28]. Anti-Her2 monoclonal antibodies, c-neuAb2 and 
c-neuAb3, were from Santa Cruz Biotechnology. Anti-phosphoty- 
rosine, PY20, was from ICN. Anti-EGFR monoclonal antibodies, 
E-2760 and E-3138, were from Sigma. 
2.3. Immunoprecipitations 
Cells were grown in 10 cm dishes to about 80% confluency, washed 
twice with DMEM and incubated with Iigand or control solution for 
5 min at 37°C. Cells were lysed in PBS/TDS buffer, lysates added to 
the protein-G-agarose-antibody complex and incubated for 2 h at 4°C. 
The immunocomplex was washed three times with PBVTDS and 2x 
SDS sample buffer was added. 
2.4. Assay of receptor tyrosine phosphorylation 
Cells were grown in 48-well plates and washed with DMEM 223 
times. Ligand solution was added to the wells and incubated for 5 min 
at 37°C. The solution was removed and the cells were solubilized with 
SDS sample buffer. The samples, with or without immunoprecipitation, 
were subjected to SDS-PAGE followed by Western blotting and prob- 
ing with anti-phosphotyrosine. 
2.5. Crosslinking assay 
NDFa2 was iodinated by the method of M.A.K. Markwell, using 
Iodo-beads (Pierce). Iodinated NDF was purified by Sephadex G-25 
column chromatography. Cells in IO cm dishes were incubated with 
“51-labeled NDF for 5-10 min at 37°C. Following a quick wash with 
DMEM, the cells were incubated with BS3 (3 mM) for 30 min at room 
temperature. The cells were lysed and Her3, Her2 or EGFR were 
immunoprecipitated from the Iysates. The samples were run on a 4% 
polyacrylamide gel. Radioactive bands were detected by phosphoimage 
analyzer (Molecular Dynamics). 
3. Results and discussion 
Her3 was immunoprecipitated from lysates of the 
breast carcinoma cell lines MDAMB453, MDAMB468 
and SKBR3 using antibodies 61.3 and 49.3 raised to two 
different synthetic peptides from the cytoplasmic domain 
of Her3 [28]. These antibodies had previously been 
shown to identify a ~160 erbB3 protein from human 
embryonal cells (293 cells) transfected with the cDNA 
encoding c-erbB3 [28]. The antibodies do not crossreact 
with c-erbB2 or EGFR (data not shown) [29]. In the 
present studies, utilizing the same two antibodies, we 
detected a 180 kDa protein in immunoprecipitates of 
SKBR3 and MDAMB453 cells (Fig. 1) which agree with 
a recent report [27]. The discrepancy in the molecular 
weight, 160 kDa vs. 180 kDa, might be explained as 
either a different degree of glycosylation of the Her3 
extracellular region, or different proteolytic processing 
between the cell lines. NDF stimulated the phosphoryla- 
tion of a band at 180 kDa, specifically immunoprecipi- 
tated by antibodies to Her3 in both MDAMB453, 
MDAMB468 and SKBR3 (data not shown) cells. 
Phosphorylated Her2 was also identified in a Her2 im- 
munoprecipitate of NDF-stimulated MDAMB453 cells 
(Fig. 2) and SKBR3 (data not shown) [23]. Since Her2, 
Her3 and Her4 are expressed in the MDAMB453 cell 
line [27], the tyrosine phosphorylation of Her3 in re- 
sponse to NDF isoforms (data not shown) may not be 
due to direct binding of NDF to Her3 but receptor- 
receptor cross-talk. Her4, however, is reported not to be 
expressed in the MDAMB468 cell line [30]. To clarify the 
nature of the interaction between NDF and Her3, CHO 
cells which do not express any type 1 receptors were 
transfected with a plasmid containing the full-length 
Her3 gene. Selected CHO/Her3 clones, #7 and # 12, were 
used for these experiments. As shown in Fig. 3A, the 
transfected CHO cells stimulated with NDF showed 
strong phosphorylation of tyrosine residues in Her3 im- 
munoprecipitates. The results strongly suggest that NDF 
is a ligand for Her3. It has been reported that NDF binds 
specifically to the protein tyrosine kinase receptor, Her4 
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Fig. I. Her3 (~180) detection with anti-Her3 (61.3 and 49.3) [28] in breast carcinoma cell lines. Her3 was detected by immunoprecipitation from cell 
lysates of MDAMB453 and SKBR3 with anti-Her3 (61.3) followed by Western blotting and probing with anti-Her3 (49.3). There was no detectable 
cross-reaction of these antibodies with Her2 (data not shown) [29]. To show differences in electrophoretic mobility between I80 and 170 kDa, EGFR 
was immunoprecipitated from A431 cell lysates and blotted with anti-EGFR. Lanes 1 and 2 are duplicates. Lanes 3 and 6 are controls, i.e. 
immunoprecipitation from cell lysing solution instead of cell lysates. Lanes 4 and 5 are duplicates from separate cell cultures. Lanes 7 and 8 are as 
shown. The low M, band in lane 8 is non-specific (see lane 6, non-cell lysate control). 
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Fig. 2. NDF induces tyrosine phosphorylation of Her3 in breast carcinoma cells. Tyrosine phosphorylated receptors were immunoprecipitated with 
anti-Her3 or anti-Her2 followed by Western blotting and probing by anti-phosphotyrosine (PTY). 
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Fig. 3. NDF and the isoforms induce tyrosine phosphorylation of Her3 in Her3/CHO cells. (A) Immunoprecipitate of Her3-positive clone 7, probed 
with anti-Her3 (49.3) shown in lane 1. Her3/CHO, plasmid/CHO and MDAMB453 cells were incubated with 50 ng/ml NDFa2 (lanes 3,5,7,9) or 
DMEM (Lanes 2,4,6,8) for 5 min at 37°C and immunoprecipitated with anti-Her3. Lanes 2 and 3 are clone 7, and lanes 4 and 5 are clone 12. Resulting 
Western blots were probed with antiPTY(PY20; ICN). (B) Her3/CHO stimulation by NDF isoforms. Lanes: I, positive control, NDFa2,,,,,, 50 
ng/ml in MDAMB453; 2, NDF/?l ,77_246r 2 nM; 3, NDFBI ,7,_246, 6 nM; 4, NDFj?l ,+-246r 2 nM; 5, NDFa2,,,,, 2 nM; 6, DMEM, negative control. 
E in lanes 2 and 3 stands for EGF structural motif. F in lanes I, 4 and 5 stands for full-length. Her3/CHO cells were seeded in 48 well plates, and 
after 24 h isoform solutions were incubated for 5 min at 37°C. Cells were solubilized with SDS sample buffer. Solubilized samples were electrophoresed 
on 8% polyacrylamide gels, followed by Western blotting and probing with anti-PTY. 
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Fig. 4. Crosslinking iodinated NDFa2 to Her3. ‘251-labeled NDFa2 or EGF was incubated in MDAMB453, MDAMB468, SKBR3 and Her3/CHO 
for 10 min at room temperature. Cells were washed with DMEM and then crosslinked with BS3 (Pierce) followed by cell lysis. Lysates were 
immunoprecipitated with antibodies to Her3, Her2 or EGFR and the samples were run on a 4% polyacrylamide gel. Radioactive protein bands were 
detected-by a phosphoimage analyzer. 
[3]. As shown in Fig. 3B, the NDF isoforms examined 
here all induced tyrosine phosphorylation of Her3 in 
Her3/CHO cells. In order to confirm the direct interac- 
tion of NDF and Her3, ‘251-labeled NDF was 
crosslinked with the chemical crosslinker BS3 in 
MDAMB453, MDAMB468, SKBR3 (which also lack 
expression of Her4 [30]) and Her3/CHO cells, followed 
by immunoprecipitation of cell lysates with either anti- 
Her3, anti-Her2 or anti-EGFR antibodies (Fig. 4). Im- 
munoprecipitation with either anti-Her3 or anti-Her2 re- 
sulted in the appearance of high Mw protein complexes 
(> 400 kDa) in MDAMB453, MDAMB468, SKBR3 
and Her3/CHO cell lysates. The results suggest that 
NDF induces receptor homo- or hetero-oligomerization 
in the breast cancer cell lines tested and in Her3 trans- 
fected cells. ‘251-labeled EGF assayed in the same binding 
and crosslinking study did not generate a A& protein 
complex, but monomer and dimer forms of the EGF 
receptor were visible in immunoprecipitates. Hetero- 
dimers of EGFR and Her2 have been detected previously 
in SKBR3 cells incubated with ‘251-labeled EGF [31]. 
Thus we show here that several isoforms of NDF in- 
duce Her3 tyrosine phosphorylation in Her3/CHO cells. 
Her3 interaction with NDF and NDF isoforms in Her3- 
transfected cells may be considered to be a model of 
naturally occurring cells, although in nature it is rare for 
cells to possess only a single type of receptor. However, 
it is more straight-forward to determine individual 
growth factor/receptor interactions which are not con- 
fused by the presence of several receptor types. At least 
ten NDF isoforms have been identified which were gen- 
erated from alternative splicing [32]. It is not yet known 
which of the NDF isoforms bind specifically to Her4. 
NDF isoforms can be grouped into two types, a and j?, 
based on differences in their receptor binding portions 
(EGF-like domains). Since all the isoforms examined 
here bind Her3 in the absence of other receptors, it ap- 
pears that Her3 may not possess isotype specificity. 
In light of the fact that Her3 and Her4 both bind 
NDF, yet Her2 still appears to be involved in biological 
responses of some cells to NDF (C. Starnes, unpublished 
data), we believe that NDF is capable of inducing a 
variety of receptor hetero-complexes, which may consist 
of various combinations of Her2, Her3 or Her4 as appro- 
priate to the particular cell line. 
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